Fig 1.
Matching weight-adjusted cumulative hazard curves for all-cause hospitalization or mortality among outpatient Veterans who were current users of an ARB/ACEI- vs. non-ARB/ACEI-based antihypertensive regimen (Panel A) and ARB user vs. ACEI user (Panel B). Cumulative incidence curves demonstrating the risk for all-cause hospitalization or mortality in outpatients between exposure groups were generated from matching-weighted Cox regression models and bootstrap resampling with 2,000 iterations. Veterans are censored at the first occurrence of all-cause hospitalization, all-cause mortality, or October 15, 2020. Numbers at risk in table are unweighted. Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CI: confidence interval; HR: hazard ratio.
Table 1.
Matching weight-adjusted incidence rates and hazard ratios for the primary and secondary outcomes among outpatient Veterans with treated hypertension who were current users of an ARB/ACEI- vs. non-ARB/ACEI-based antihypertensive regimen and ARB user vs. ACEI user, separately.
Fig 2.
Matching weight-adjusted cumulative hazard curves for all-cause mortality among inpatient Veterans who were current users of an ARB/ACEI- vs. non-ARB/ACEI-based antihypertensive regimen (Panel A) and ARB user vs. ACEI user (Panel B). Cumulative incidence curves demonstrating the risk for all-cause mortality in inpatients between exposure groups were generated from matching-weighted Cox regression models and bootstrap resampling with 2,000 iterations. Veterans are censored at the first occurrence of all-cause mortality, 30 days’ follow-up, or October 15, 2020. Numbers at risk in table are unweighted. Due to small sample size, results displayed in Panel A are exploratory. Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CI: confidence interval; HR: hazard ratio.
Table 2.
Matching weight-adjusted incidence rates and hazard ratios for the primary and secondary outcomes among inpatient Veterans with treated hypertension who were current users of an ARB/ACEI- vs. non-ARB/ACEI-based antihypertensive regimen and ARB user vs. ACEI user, separately.